For instance, alterations in TP53 and ATM, due to deletions or mutations, have been associated with poor prognosis and chemoresistance in chronic lymphocytic leukemia (CLL) and their detection has become clinically necessary [37,38,39]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.